LAVA Therapeutics N.V.
LVTXNASDAQHealthcare
$1.74
$-0.07(-3.87%)
Market Cap$45771213
P/E Ratio—
52W High$2
52W Low$0.85
LAVA Therapeutics N.V. (LVTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LVTX · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 6, 2025EPS Actual
-$0.27
Est. -$0.23 · -17.4%
Revenue
—
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 6, 2025
After Market Close
▼ Miss EPS
LVTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.23 | -$0.27 | -17.4% | — | — | — |
| ▼ Q3 FY2025 | Aug 13, 2025 | -$0.28 | -$0.32 | -14.3% | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.37 | -$0.13 | +64.9% | — | — | — |
| ▲ Q1 FY2025 | Mar 28, 2025 | -$0.32 | -$0.14 | +56.3% | $0.01B | $0.00B | +106.7% |
| ▼ Q4 FY2024 | Dec 10, 2024 | -$0.33 | -$0.46 | -39.4% | — | $0.00B | — |
| ▲ Q3 FY2024 | Aug 20, 2024 | -$0.33 | -$0.31 | +6.1% | — | — | — |
| ▲ Q2 FY2024 | May 21, 2024 | -$0.25 | -$0.02 | +92.0% | $0.01B | $0.00B | +221.9% |
| ▼ Q1 FY2024 | Mar 20, 2024 | $0.16 | -$0.24 | -250.0% | $0.00B | $0.01B | -93.8% |
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.27
EPS Est.
-$0.23
EPS Surpr.
-17.4%
Revenue
—
Q3 FY2025
Aug 13, 2025Miss
EPS Actual
-$0.32
EPS Est.
-$0.28
EPS Surpr.
-14.3%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.37
EPS Surpr.
+64.9%
Revenue
—
Q1 FY2025
Mar 28, 2025Beat
EPS Actual
-$0.14
EPS Est.
-$0.32
EPS Surpr.
+56.3%
Revenue
$0.01B
Q4 FY2024
Dec 10, 2024Miss
EPS Actual
-$0.46
EPS Est.
-$0.33
EPS Surpr.
-39.4%
Revenue
—
Q3 FY2024
Aug 20, 2024Beat
EPS Actual
-$0.31
EPS Est.
-$0.33
EPS Surpr.
+6.1%
Revenue
—
Q2 FY2024
May 21, 2024Beat
EPS Actual
-$0.02
EPS Est.
-$0.25
EPS Surpr.
+92.0%
Revenue
$0.01B
Q1 FY2024
Mar 20, 2024Miss
EPS Actual
-$0.24
EPS Est.
$0.16
EPS Surpr.
-250.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q3 FY2026 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Q2 FY2026 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q1 FY2026 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Q4 FY2025 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q3 FY2025 | $-0.24 | $-0.24 | $-0.24 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 6, 2025 | -17.4% | $1.62 | $1.62 | +0.00% |
| ▼ Q3 FY2025 | Aug 13, 2025 | -14.3% | $1.53 | $1.53 | +0.00% |
| ▲ Q2 FY2025 | May 14, 2025 | +64.9% | $1.25 | $1.27 | +1.60% |
| ▲ Q1 FY2025 | Mar 28, 2025 | +56.3% | $1.30 | $1.29 | -0.77% |
| ▼ Q4 FY2024 | Dec 10, 2024 | -39.4% | $1.91 | $1.46 | -23.56% |
| ▲ Q3 FY2024 | Aug 20, 2024 | +6.1% | $1.82 | $1.81 | -0.55% |
| ▲ Q2 FY2024 | May 21, 2024 | +92.0% | $2.70 | $2.65 | -1.85% |
| ▼ Q1 FY2024 | Mar 20, 2024 | -250.0% | $3.19 | $3.07 | -3.76% |
Q4 FY2025+0.00%
Report Date
Nov 6, 2025
EPS Beat/Miss
-17.4%
Price Before
$1.62
Price After
$1.62
Q3 FY2025+0.00%
Report Date
Aug 13, 2025
EPS Beat/Miss
-14.3%
Price Before
$1.53
Price After
$1.53
Q2 FY2025+1.60%
Report Date
May 14, 2025
EPS Beat/Miss
+64.9%
Price Before
$1.25
Price After
$1.27
Q1 FY2025-0.77%
Report Date
Mar 28, 2025
EPS Beat/Miss
+56.3%
Price Before
$1.30
Price After
$1.29
Q4 FY2024-23.56%
Report Date
Dec 10, 2024
EPS Beat/Miss
-39.4%
Price Before
$1.91
Price After
$1.46
Q3 FY2024-0.55%
Report Date
Aug 20, 2024
EPS Beat/Miss
+6.1%
Price Before
$1.82
Price After
$1.81
Q2 FY2024-1.85%
Report Date
May 21, 2024
EPS Beat/Miss
+92.0%
Price Before
$2.70
Price After
$2.65
Q1 FY2024-3.76%
Report Date
Mar 20, 2024
EPS Beat/Miss
-250.0%
Price Before
$3.19
Price After
$3.07
Avg Beat Reaction-0.39%
Avg Miss Reaction-6.83%
Beat Rate4 / 8 quarters
Largest Move-23.56% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LVTX ends December
LAVA Therapeutics N.V. (LVTX) most recently reported earnings on November 6, 2025 for Q4 FY2025, posting EPS of $-0.27 — missing the analyst consensus of $-0.23 by -17.4%. The next LVTX earnings date is expected around September 1, 2026.
Each quarter, investors track LVTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LVTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LVTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LVTX earnings · 5 questionsLAVA Therapeutics N.V.'s next earnings report is expected around September 1, 2026. LVTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LVTX historically reports after market close (AMC).
LVTX earnings datewhen is LVTX earningsLVTX next earnings datewhen does LVTX report earningsLVTX earnings calendar
▸ Source: FMP · LAVA Therapeutics N.V. SEC filings · US GAAP · LAVA Therapeutics N.V. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026